Table 6.

Colchicine in percutaneous intervention.

First author (study name)	Study type	Patient number	Clinical setting	Colchicine dosage and duration	Adverse events	Summary and Comment
O'Keefe [45], 1992	Prospective double-blinded, randomized control trial	197	Prevention of restenosis After PTCA (balloon angioplasty).	0.6mg/BD started within 24 h of angioplasty continued for 6 months	Colchicine 28% vs placebo 5%.	Restenosis: colchicine 41%, vs placebo 45%, p = NS
Freed M [46], 1995	Open label trial	50		Prevention of neointimal	Hyperplasia after PTCA (balloon angioplasty) in combination of enalapril and statin.	0.6mg BD 1 day before angiography and until follow up angiography.
18%	Restenosis: Colchicine 51%.	Deftereos [47], 2013	Double-blind, prospective, placebo-controlled study	196	Prevention of restenosis in diabetic patients undergoing BMS implantation.	Colchicine 0.5mg BD was administered for 6 months from the day of the index PCI (within 24 h, until follow-up angiograph.

Colchicine 17% vs placebo 7%, p=0.058

Restenosis: Colchicine 16% vs placebo 33%, p= 0.007, NNT 6.

BMS= bare metal stent, PTCA = percutaneous transcatheter angioplasty, NNT = number needed to treat, NS = non-significant.